Company Focus
Bayer
Latest Bayer News
Biotechnology
German pharma major Bayer’s wholly-owned and independently operated subsidiary AskBio has announced the presentation of baseline participant characteristics from GenePHIT, one of the largest randomized gene therapy trials conducted in heart failure to date. 1 September 2026
Related News
Insights
Company Spotlight
A South Korean biotechnology company developing next-generation biobetters and biosimilars through proprietary platform technologies, with its human hyaluronidase ALT-B4 attracting a growing roster of global pharmaceutical partners.
Latest News & Features of interest to Bayer
Generics
RedHill Biopharma on Monday announced the divestment of its 70% stake in the Talicia business to a subsidiary of Apotex Health for an upfront payment of $18 million plus up to an additional $35 million in potential payments based on worldwide net sales milestones. 1 September 2026
Biotechnology
US biotech major Amgen has announced new findings showing Repatha (evolocumab) reduced the risk of death in high-risk adults without a prior heart attack or stroke when added to statins or other low-density lipoprotein cholesterol (LDL-C)-lowering treatments. 1 September 2026
Biotechnology
German pharma major Bayer’s wholly-owned and independently operated subsidiary AskBio has announced the presentation of baseline participant characteristics from GenePHIT, one of the largest randomized gene therapy trials conducted in heart failure to date. 1 September 2026
Biotechnology
Significant research news last week included Regenxbio suffering a further setback in the development of RGX-121, with the US Food and Drug Administration (FDA) putting a clinical hold on its clinical trial. The FDA approved Jazz Pharmaceuticals and Zymeworks partnered cancer drug Ziihera for new indications, and Revolution Medicines won FDA approval for its Rasonque for the treatment pf pancreatic cancer. On the deal-making front, Biohaven granted a global license for its opakalim to South Korea’s SK Biopharmaceutical that could earn it $795 million. 30 August 2026
Pharmaceutical
Japan’s largest drugmaker Takeda announced that the US Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Mimrylo (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. 29 August 2026
Biotechnology
China-based biotech DualityBio today announced that it has entered into a collaboration and license agreement with Genentech, a Roche subsidiary, to develop next-generation antibody-drug conjugates (ADCs) built on the company's proprietary DualityBio Unique Payload Antibody Conjugate (DUPAC) platform. 28 August 2026
Biotechnology
ProFound Therapeutics, a Flagship Pioneering company based in Cambridge, Massachusetts, has received an investment commitment of up to $35 million from the Gates Foundation, including an initial $20 million payment, to support drug target and biomarker discovery for preeclampsia and eclampsia. 28 August 2026
Biotechnology
US cardiovascular biotech Cytokinetics has presented full results from ACACIA-HCM, the pivotal Phase III trial of Myqorzo (aficamten) in symptomatic non-obstructive HCM (nHCM), in the Hot Line 1 session at ESC Congress 2026 in Munich. Results were simultaneously published in The New England Journal of Medicine. 28 August 2026
Biotechnology
Swiss pharma major Roche has announced new two-year data from the Phase IIIb/IV SALWEEN study of Vabysmo (faricimab), presented at the 19th Asia-Pacific Vitreo-retina Society Congress in Australia on Friday. 28 August 2026
Biotechnology
US biotech major Moderna plans to raise $2 billion through a private placement of convertible senior notes due 2032, offered to qualified institutional buyers under Rule 144A. Initial purchasers will get a 13-day option to take up to $300 million of additional notes, which would lift the total to $2.3 billion. 28 August 2026
Latest In Brief for Bayer
Pharmaceutical
Spanish drugmaker PharmaMar has announced that health authorities in Canada, Qatar and South Korea have approved Zepzelca (lurbinectedin) in combination with atezolizumab (Roche’s Tecentriq) for the maintenance treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed following first-line induction therapy with atezolizumab, carboplatin and etoposide. 25 August 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze